Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Carlota PascoalUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0000-0001-5049-0579
Mylène A CarrascalUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0000-0002-3391-543X
Daniela F BarreiraUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0000-0002-3391-2220
Rita A LourençoUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.
Pedro GranjoUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.
Ana R GrossoUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0000-0001-6974-4209
Paula BorralhoInstituto de Anatomia Patológica, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal.
Sofia BragaUnidade de Mama, Instituto CUF de Oncologia, 1998-018 Lisboa, Portugal.
Paula A VideiraUCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.ORCID 0000-0001-5987-2485
Funding
Fundação para a Ciência e Tecnologia 2020.09880.BDFundação para a Ciência e Tecnologia LA/P/0140/202Fundação para a Ciência e Tecnologia SFRH/BD/100970/2014Fundação para a Ciência e Tecnologia SFRH/BD/138647/2018Fundação para a Ciência e Tecnologia SFRH/BD/148480/2019Fundação para a Ciência e Tecnologia UIDB/04378/2020Fundação para a Ciência e Tecnologia UIDP/04378/2020GlycoCan Marie Curie Actions 676421Liga Portuguesa Contra o Cancro LPCC/Pfizer2011Tagus Tank CUF-NOVA Medical School 2018
6 · The paper itself
Abstract
Triple-negative breast cancer (TNBC) encompasses multiple entities and is generally highly aggressive and metastatic. We aimed to determine the clinical and biological relevance of Sialyl-Lewis X and A (sLe
Indexed as
aberrant glycosylationcytokeratin expressiondisease-free survival rateintermediate filament proteinssialyl LewisX/A (sLeX/A)triple-negative breast cancer (TNBC)α6 integrin
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.